Searching for your content...
In-Language News
Contact Us
888-776-0942 from 8 AM - 10 PM ET
Photocure ASA (OSE: PHO) reports Hexvix®/Cysview® revenues of NOK 97.7 million in the fourth quarter of 2020 (Q4 2019: NOK 58.8). Product revenues...
Photocure ASA (PHO:OSE): The Bladder Cancer Company focused on delivering transformative solutions to improve the lives of bladder cancer patients,...
Photocure ASA (OSE:PHO) today announced new data and analyses presented at the 21st Annual Meeting of the Society of Urologic Oncology (SUO)....
Photocure ASA (OSE:PHO) today reported Hexvix®/Cysview® revenues of NOK 49.6 million in the third quarter of 2020 (Q3 2019: NOK 51.1), with the U.S....
Photocure ASA (OSE:PHO) today announces a highlight from the BLADDR 2020 congress, a poster presentation on new findings from the Nordic Flexible BLC ...
Photocure ASA (OSE:PHO) today announces that the European Patent Office (EPO) has granted patent EP 2983780 covering the commercial Cevira® device in ...
Photocure ASA (OSE:PHO) reported Hexvix®/Cysview® revenues of 53.5 million in the second quarter of 2020 (Q2 2019: NOK 52.1), corresponding to growth ...
Photocure ASA (OSE: PHO), today announced the appointment of Genotests SpA as the exclusive distributor for the commercialization of Hexvix® in Chile....
Asieris Pharmaceuticals (Asieris), a China-based biotech company with global aspirations to discover, develop and commercialize innovative drugs for...
Photocure ASA (OSE:PHO), today announced the appointment of Susanne Strauss as Vice President and General Manager of Europe, effective 1 July 2020....
Reference is made to the OSE notification 27 April 2020 from Photocure ASA (PHO: OSE) regarding the return of Hexvix® sales, marketing and...
Photocure ASA (OSE: PHO), held its annual general meeting on 10 June 2020 at 17:00 hours (CET). All proposals were resolved as presented in the...
Photocure ASA (OSE: PHO) today announces the company's first sustainability report, which will be presented at the Annual General Meeting (AGM) at...
Photocure ASA (OSE: PHO) today announced key data was published by the 2020 American Urological Association (AUA) Annual Virtual Meeting. Three...
Photocure ASA (OSE:PHO) announced the first quarter 2020 results in the trading update 27 April 2020, stating a revenue growth of 33% for the U.S....
Photocure ASA (Photocure, PHO: OSE) has reached an agreement with Ipsen Pharma SAS (Ipsen) on key terms for the return of Hexvix sales, marketing and ...
Photocure ASA (OSE: PHO), today reported a revenue growth of 51% for the U.S. market in the fourth quarter of 2019, contributing to Hexvix/Cysview...
Photocure ASA (OSE: PHO), today reported a revenue growth of 42% in local currency for the U.S. market in the third quarter of 2019, contributing to...
Photocure ASA., (OSE: PHO), The United States Centers for Medicare and Medicaid Services (CMS) has released its Final Rule maintaining the...
Photocure ASA (OSE: PHO) today announced key data presented at the 2019 American Urological Association (AUA) Annual Meeting in Chicago. Session...
Photocure ASA (OSE: PHO), May 16, 2018, announced today the launch of Blue Light Cystoscopy (BLC™) with Cysview for a new indication of surveillance...
Photocure ASA (OSE: PHO), announced today that the U.S. Food and Drug Administration (FDA) approved its supplemental new drug application (sNDA) to...
In a retrospective study Hexvix fluorescence-guided bladder resection significantly improved overall survival and recurrence free survival compared...
Photocure (OSE: PHO), a Norwegian specialty pharmaceutical company focused in dermatology and cancer, today announced positive results from its...
Join PR Newswire for Journalists to access all of the free services designated to make your job easier.
In need of subject matter experts for your story? Submit a free ProfNet request and find the sources you need.